Invesco
MRVI icon

Invesco’s Maravai LifeSciences MRVI Stock Holding History

Invesco’s Portfolio MRVI Stock Details MRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.57M Buy
572,160
+220,602
+63% +$952K ﹤0.01% 2353
2026
Q1 		$995K Buy
351,558
+5,785
+2% +$19.6K ﹤0.01% 2863
2025
Q4 		$1.12M Buy
345,773
+37,958
+12% +$128K ﹤0.01% 2861
2025
Q3 		$883K Buy
307,815
+25,623
+9% +$65.4K ﹤0.01% 2989
2025
Q2 		$680K Buy
282,192
+40,495
+17% +$85.1K ﹤0.01% 3030
2025
Q1 		$534K Buy
241,697
+15,751
+7% +$62.2K ﹤0.01% 3121
2024
Q4 		$1.23M Buy
225,946
+17
+0% +$109 ﹤0.01% 2830
2024
Q3 		$1.88M Sell
225,929
-2,258
-1% -$19.5K ﹤0.01% 2632
2024
Q2 		$1.63M Sell
228,187
-411,779
-64% -$3.55M ﹤0.01% 2680
2024
Q1 		$5.55M Buy
639,966
+426,644
+200% +$2.89M ﹤0.01% 2169
2023
Q4 		$1.4M Buy
213,322
+55,575
+35% +$359K ﹤0.01% 2752
2023
Q3 		$1.58M Sell
157,747
-225,588
-59% -$2.48M ﹤0.01% 2685
2023
Q2 		$4.76M Buy
383,335
+29,674
+8% +$401K ﹤0.01% 2269
2023
Q1 		$4.95M Sell
353,661
-38,045
-10% -$546K ﹤0.01% 2225
2022
Q4 		$5.61M Sell
391,706
-1,121,935
-74% -$17.7M ﹤0.01% 2189
2022
Q3 		$38.6M Buy
1,513,641
+39,021
+3% +$979K 0.01% 995
2022
Q2 		$41.9M Buy
1,474,620
+246,837
+20% +$7.82M 0.01% 996
2022
Q1 		$43.3M Sell
1,227,783
-112,851
-8% -$3.78M 0.01% 1060
2021
Q4 		$56.2M Sell
1,340,634
-1,803,270
-57% -$73M 0.01% 999
2021
Q3 		$154M Sell
3,143,904
-1,042,424
-25% -$50.8M 0.04% 623
2021
Q2 		$175M Buy
4,186,328
+158,590
+4% +$6.15M 0.04% 595
2021
Q1 		$144M Buy
4,027,738
+76,302
+2% +$2.53M 0.04% 634
2020
Q4 		$111M Buy
+3,951,436
New +$110M 0.03% 687

Other funds holding MRVI

GL
GTCR LLC Chicago, Illinois $3.91B AUM 14.64% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
1WCM
12 West Capital Management New York $535M AUM 25.99% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OAM
Ophir Asset Management Sydney, Australia $1.22B AUM 100.03% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return

Invesco's MRVI Position: Q2 2026 in Review

Invesco increased its Maravai LifeSciences (MRVI) stake by 63% in Q2 2026, buying an estimated $952K and bringing the position to 572,160 shares worth $3.57M. The position accounts for ﹤0.01% of the portfolio, ranked #2353.

Invesco first reported a position in MRVI in Q4 2020 and has held it in 23 quarters since. The position peaked at $175M in Q2 2021. 178 funds tracked by Wall St. Rank hold MRVI as of Q2 2026.

  • Invesco held 572,160 shares of Maravai LifeSciences worth $3.57M as of Q2 2026.
  • Invesco bought 220,602 Maravai LifeSciences shares in Q2 2026, an estimated $952K.
  • Maravai LifeSciences made up ﹤0.01% of Invesco's portfolio in Q2 2026, its #2353 holding.
  • Invesco first reported a position in Maravai LifeSciences in Q4 2020 and has held it in 23 quarters since.
  • Invesco's Maravai LifeSciences position peaked at $175M in Q2 2021.
  • 178 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q2 2026.

Based on Invesco's 13F filing for Q2 2026, filed 14 Aug 2026.